AstraZeneca PLC and its global biologics R&D arm, MedImmune, have pushed back the timeline for the final results of the Phase III MYSTIC trial of Imfinzi (durvalumab). The delay is not necessarily more negative for the product's overall prospects in late-stage lung cancer but could provide a small additional boost for rival Merck & Co's Keytruda (pembrolizumab).
AstraZeneca MYSTIC Read-Out Delay Further Boost To Merck
Overall survival data are now not due until the second half of the year but however they turn out competitor Merck & Co is still expected to dominate the late-stage NSCLC market with Keytruda.
